Rebetol and Dermatitis atopic aggravated - a phase IV clinical study of FDA data

Summary:

Dermatitis atopic aggravated is reported only by a few people who take Rebetol.

The phase IV clinical study analyzes which people take Rebetol and have Dermatitis atopic aggravated. It is created by eHealthMe based on reports of 25,882 people who have side effects while taking Rebetol from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 18, 2023

25,882 people reported to have side effects when taking Rebetol.
Among them, 3 people (0.01%) have Dermatitis atopic aggravated.

What is Rebetol?

Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,907 Rebetol users for its effectiveness, alternative drugs and more.

What is Dermatitis atopic aggravated?

Dermatitis atopic aggravated (aggravated inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 621 drugs and 145 conditions by eHealthMe.

Number of Rebetol and Dermatitis atopic aggravated reports submitted per year:

Could Rebetol cause Dermatitis atopic aggravated?

Time on Rebetol when people have Dermatitis atopic aggravated *:

Gender of people who have Dermatitis atopic aggravated when taking Rebetol *:

female: 100 %
male: 0.0 %

Age of people who have Dermatitis atopic aggravated when taking Rebetol *:

Common drugs people take besides Rebetol *:

Pegasys: 2 people, 66.67%
Sovaldi: 1 person, 33.33%

Common side effects people have besides Dermatitis atopic aggravated *:

Upper Respiratory Tract Infection: 2 people, 66.67%
Thrombocytopenia (decrease of platelets in blood): 2 people, 66.67%
Rectal Haemorrhage (bleeding from anus): 2 people, 66.67%
Pneumonia: 2 people, 66.67%
Photosensitivity Reaction: 2 people, 66.67%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 2 people, 66.67%
Fever: 2 people, 66.67%
Febrile Neutropenia (fever with reduced white blood cells): 2 people, 66.67%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 2 people, 66.67%
Drug Eruption (adverse drug reaction of the skin): 2 people, 66.67%

Common conditions people have *:

Hepatitis C: 2 people, 66.67%
Nausea (feeling of having an urge to vomit): 1 person, 33.33%
Injection Site Pruritus (severe itching at injection site): 1 person, 33.33%
Headache (pain in head): 1 person, 33.33%
Dermatitis Contact (skin reaction (dermatitis) resulting from exposure to allergens): 1 person, 33.33%
Back Pain: 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rebetol and have Dermatitis atopic aggravated?

Check whether Dermatitis atopic aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

Related studies

How severe was Dermatitis atopic aggravated and when was it recovered:

Dermatitis atopic aggravated in Rebetol

Expand to all the drugs that have ingredients of ribavirin:

Dermatitis atopic aggravated and drugs with ingredients of ribavirin

Alternative drugs to, pros and cons of Rebetol:

Rebetol (25,907 reports)

Common Rebetol side effects:

Fatigue (feeling of tiredness): 2,064 reports
Rashes (redness): 1,812 reports
Thrombocytopenia (decrease of platelets in blood): 1,709 reports
Fever: 1,629 reports
Weakness: 1,422 reports
Depression: 1,377 reports

Browse all side effects of Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Dermatitis atopic aggravated treatments and more:

Dermatitis atopic aggravated (30 reports)

COVID vaccines that are related to Dermatitis atopic aggravated:

Common drugs associated with Dermatitis atopic aggravated:

All the drugs that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (622 drugs)

Common conditions associated with Dermatitis atopic aggravated:

Asthma: 359 reports

All the conditions that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (145 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Rebetol) and Rebetol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.